On this page
What each program costs in Vermont
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $59/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | medication monthly, membership yearly | $75/mo | $199/yr, included | 4.8 (288 reviews) | Visit | ||
| 6 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 7 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.2 (218 reviews) | Visit | ||
| 10 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 11 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 12 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 13 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 14 | Microdosing Tirzepatide | 12-month plan, $2,028 up front | $169/mo | none | 4.0 (162 reviews) | Visit | ||
| 15 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 16 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 17 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 18 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 19 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Does Vermont Medicaid (Green Mountain Care) cover GLP-1s for weight loss?
Not covered for weight loss
Vermont Medicaid's preferred drug list says drugs used for weight loss are excluded from coverage, so it does not cover Wegovy or Zepbound for weight loss. Read from state documents Nov 6, 2026.
What Vermont Medicaid (Green Mountain Care)'s documents say about each drug for weight loss. Read Nov 6, 2026. Department of Vermont Health Access.
WegovyNo
Criteria cover heart risk reduction with a BMI over 27 and a listed event, and MASH with fibrosis (injection only), in members without diabetes.
“Drugs used for weight loss, drugs used to promote fertility, and drugs used for cosmetic purposes or hair growth are excluded from coverage under the Vermont Medicaid Pharmacy program.”
Department of Vermont Health Access · Effective Oct 2, 2026 · read Nov 6, 2026
“Medication is not being used for weight loss only”
Department of Vermont Health Access · Effective Oct 2, 2026 · read Nov 6, 2026
ZepboundNo
Criteria cover obstructive sleep apnea shown by a sleep study, with a BMI over 30 and prescribed CPAP, without type 2 diabetes.
“Drugs used for weight loss, drugs used to promote fertility, and drugs used for cosmetic purposes or hair growth are excluded from coverage under the Vermont Medicaid Pharmacy program.”
Department of Vermont Health Access · Effective Oct 2, 2026 · read Nov 6, 2026
“Patient has a diagnosis of obstructive sleep apnea (OSA) demonstrated by a sleep study”
Department of Vermont Health Access · Effective Oct 2, 2026 · read Nov 6, 2026
OzempicNo
GLP-1 class criteria require a type 2 diabetes diagnosis.
“Drugs used for weight loss, drugs used to promote fertility, and drugs used for cosmetic purposes or hair growth are excluded from coverage under the Vermont Medicaid Pharmacy program.”
Department of Vermont Health Access · Effective Oct 2, 2026 · read Nov 6, 2026
“Clinical criteria for all drugs: patient has a diagnosis of Type 2 Diabetes Mellitus.”
Department of Vermont Health Access · Effective Oct 2, 2026 · read Nov 6, 2026
MounjaroNo
GLP-1 class criteria require a type 2 diabetes diagnosis.
“Drugs used for weight loss, drugs used to promote fertility, and drugs used for cosmetic purposes or hair growth are excluded from coverage under the Vermont Medicaid Pharmacy program.”
Department of Vermont Health Access · Effective Oct 2, 2026 · read Nov 6, 2026
“Clinical criteria for all drugs: patient has a diagnosis of Type 2 Diabetes Mellitus.”
Department of Vermont Health Access · Effective Oct 2, 2026 · read Nov 6, 2026
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from Department of Vermont Health Access documents. KFF's January 2026 map listed this program as not covered; the documents we read agree.
Weight loss
Not covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
1,200 prescriptions
Ozempic and Mounjaro, 2025
9,537 prescriptions
Neighbours covering weight loss
0 of 3
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your Vermont Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed Vermont Medicaid as "not covered" for GLP-1s for obesity under fee-for-service.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether Vermont Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does Vermont Medicaid pay for?
17,163 GLP-1 prescriptions in 2025, 48th of the 50 states and DC, with $18.5 million reimbursed before rebates. Counting the share other payers covered, $18.5 million.
Prescriptions, 2025
17,163
48th of 51
Medicaid paid
$18.5M
48th of 51, before rebates
Per prescription
$1,077
$1,051 nationally
Weight-loss brands
7.0%
18th highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. Vermont is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 7.0% of Vermont Medicaid's GLP-1 prescriptions in 2025 (1,200). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Ozempic was Vermont Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Ozempic | 7,813 | 46% | $8.8 million | $1,121 |
| Trulicity | 5,762 | 34% | $6.1 million | $1,061 |
| Mounjaro | 1,724 | 10% | $1.7 million | $990 |
| Zepboundapproved for weight management | 1,059 | 6.2% | $1.1 million | $1,011 |
| Rybelsus | 439 | 2.6% | $542,893 | $1,237 |
| Victoza | 225 | 1.3% | $165,363 | $735 |
| Wegovyapproved for weight management | 141 | 0.8% | $122,550 | $869 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
On Medicare in Vermont?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
Vermont and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
None of the 3 states next to Vermont covers GLP-1s for weight loss through Medicaid. None has a lower cash floor than Vermont's $39.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| Vermont | Not covered | 19 | $39/mo |
| Massachusetts | Not covered | 18 | $39/moWellmedr |
| New Hampshire | Not covered | 19 | $39/moWellmedr |
| New York | Not covered | 19 | $39/moWellmedr |






















